HMGB-1 as a Target for Inflammation Controlling

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 3, 2012, Pages 201-209

  Nogueira Machadoa, José A ^a   de Oliveira Volpea, Caroline M ^a  

^a Hospital Santa Casa de Belo Horizonte   (Brazil)

Author keywords

Cytokines; HMGB 1; Inflammation; Patents; RAGE; TLR2 4

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMIDINOHYDRAZONE; ANGIOGENIC FACTOR; CELL ADHESION MOLECULE; CHOLINESTERASE INHIBITOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; NUCLEIC ACID; POLYCLONAL ANTIBODY; POLYPEPTIDE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PYRUVIC ACID DERIVATIVE; PYRUVIC ACID ETHYL ESTER; RECOMBINANT PROTEIN; TANSHINONE; THROMBOMODULIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CELL NUCLEUS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DOWN REGULATION; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; HEMATOPOIETIC CELL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR UPREGULATION; SEPSIS; SIGNAL TRANSDUCTION; SYNOVITIS; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; THROMBOMODULIN; TOLL-LIKE RECEPTOR 2;

EID: 84866641898     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412802481784     Document Type: Article

References (108)

1. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192(4): 565-70.
2. Pusterla T, de Marchis F, Palumbo R, Bianchi ME. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 2009; 42(4): 308-10.
3. Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22(3): 276-80.
4. Nemeth MJ, Cline AP, Anderson SM, Garrett-Beal LJ, Bodine DM. Hmgb3 deficiency deregulates proliferation and differentiation of common lymphoid and myeloid progenitors. Blood 2005; 105(2): 627-34.
5. Ronfani L, Ferraguti M, Croci L, Ovitt CE, Scholer HR, Consalez GG, et al. Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein HMGB2. Development 2001; 128(8): 1265-73.
6. Nemeth MJ, Curtis DJ, Kirby MR, Garrett-Beal LJ, Seidel NE, Cline AP, et al. HMGB3: An HMG-box family member expressed in primitive hematopoietic cells that inhibits myeloid and B-cell differentiation. Blood 2003; 102(4): 1298-306.
7. Oshima G, Shinoda M, Tanabe M, Ebinuma H, Nishiyama R, Takano K, et al. Increased plasma levels of high mobility group Box 1 in patients with acute liver failure. Eur Surg Res 2012; 48(3): 154-62.
8. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 2003; 9(1-2): 37-45.
9. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B, et al. High mobility group box protein 1: An endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173(1): 307-13.
10. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. Reversing established sepsis with antagonists of endogenous highmobility group box 1. Proc Natl Acad Sci USA 2004;101(1): 296-301.
11. Watson M, Stott K, Thomas JO. Mapping intramolecular interactions between domains in HMGB1 using a tail-truncation approach. J Mol Biol 2007; 374(5): 1286-97.
12. Zurolo E, Iyer A, Maroso M, Carbonell C, Anink JJ, Ravizza T, et al. Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 2011; 134(Pt 4): 1015-32.
13. Jacobs SR, Damania B. NLRs, inflammasomes, and viral infection. J Leukoc Biol 2012; [Epub ahead of print].
14. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117(25): 3216-26.
15. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418(6894): 191-5.
16. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201(7): 1135-43.
17. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285(5425): 248-51.
18. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10(11): 1216-21.
19. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999; 126(2): 389-92.
20. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 2005; 78(1): 1-8.
21. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270(43): 25752-61.
22. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274(28): 19919-24.
23. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279(9): 7370-7.
24. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010; 33(4): 861-8.
25. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009; 52(8): 1665-8.
26. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: Guiding immunity from within. Trends Immunol 2005; 26(7): 381-7.
27. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5(4): 331-42.
28. Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 2006; 82(5): 807-15.
29. Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 2008; 36(8): 2407-13.
30. Li YH, Kuo CH, Shi GY, Wu HL. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci 2012; 19: 34.
31. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003; 17(10): 1295-7.
32. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38.
33. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: High mobility group box-1 and cancer. Clin Cancer Res 2007; 13(10): 2836-48.
34. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7: 17.
35. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002; 72(6): 1084-91.
36. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, et al. High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis Rheum 2002; 46(10): 2598-603.
37. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48(4): 971-81.
38. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41(10): 1241-8.
39. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40(11): 1286-92.
40. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000; 16(3): 192-201.
41. Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006; 25(1): 4-11.
42. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45(6): 805-12.
43. Syed MA, Barinas-Mitchell E, Pietropaolo SL, Zhang YJ, Henderson TS, Kelley DE, et al. Is type 2 diabetes a chronic inflammatory/ autoimmune disease? Diabetes Nutr Metab 2002; 15(2): 68-83.
44. Tracey KJ. Fat meets the cholinergic antiinflammatory pathway. J Exp Med 2005; 202(8): 1017-21.
45. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63(4): 582-92.
46. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: Mechanism of activation. Diabetes 2008; 57(11): 3090-8.
47. Han J, Zhong J, Wei W, Wang Y, Huang Y, Yang P, et al. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008;57(8): 2118-27.
48. Matsuoka N, Itoh T, Watarai H, Sekine-Kondo E, Nagata N, Okamoto K, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010; 120(3): 735-43.
49. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010; 1799(1-2): 149-56.
50. Wu, H., Allan, C.B., Gao, C., An, L. L, Kiener, P., Mao, S.Y., Coyle, A. High affinity antibodies against HMGB1 and methods of use thereof. US20060099207 (2006).
51. Newman, W., Qin, S., O'Keefe, T.L., Obar, R.A. Monoclonal antibodies against HMGB1. US20080113385 (2008) & US7288250 (2004).
52. Yamada, S., Yakabe, K. Avian-derived antibody capable of binding specifically to human HMGB1, immunological determination method for human HMGB1, and, immunological determination reagent for human HMGB1. US20090297546 (2009).
53. Wahren-Herlenius, M., Nyberg, F., Marchini, G. Use of HMGB1 antagonists for the treatment of inflammatory skin conditions. US20100040608 (2010).
54. Griffioen, A.W., Van Beijnum, J.R. Tumor angiogenesis associated genes and a method for their identifications. US20110229483 (2011).
55. Messmer, D. Antibodies against HMGB1 and fragments thereof. US20110268738 (2011).
56. Wu, H., Gao, C., An, L. L, Kiener, P., Mao, S.Y., Coyle, A., Tian, J. High affinity antibodies against HMGB1 and methods of use thereof. US7964706 (2006).
57. Nishibori, M., Mori, S., Takahashi, H., Tomono, Y., Date, I., Ono, S. Method of preventing cerebral vasospasm with anti-HMGB1 antibody. US8071098 (2007).
58. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165(6): 2950-4.
59. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48(7): 2052-8.
60. Tracey, K.J., Wang, H., Sama, A.E. Inhibition of HMGB1 release by fetuin. US20060258579 (2006).
61. Zamora, R., Ford, H.R., Sielecki-Dzurdz, T., de la Cruz, V.F. HMGB1 expression and protective role os Semapimod in NEC. US20070282005 (2007).
62. Tracey, K.J., Pavlov, V.A. Cholineterase inhibitors for treating inflammation. US20080070901 (2008).
63. Shin, J.S., Youn, J.H. Methods for the treatment of disease associated with the secretion of HMGB1. US20080103086 (2008).
64. Barone, D.G., Bianchi, M.E., Bucci, E.M., Fumero, S., Valente, M., Sapio, R., Musumeci, D. Therapeutic agents for the treatment of HMGB1-related pathologies. US20080305073 (2008).
65. Wu, H., An, L.L., Kiener, P., Coyle, A., Tian, J, Gao, C. Antagonists of HMGB1 and/or Rage and methods of use thereof. US20080311122 (2008).
66. Fumero, S., Pilato, F., Barone, D., Rossa, L.B.R., Mainero, V., Traversa, S. Use of K-252a and kinase inhibitors for the prevention or treatment of HMGB1-associated pathologies. US20090191253 (2009).
67. Vater, A., Massch, C., Klusmann, S., Purschke, W., Eulber, D., Jarosch, F., Buchner, K. Novel use of spiegelmers. US20090192100 (2009).
68. Wang, H., Chen, D., Sama, A.E. Inhibition of inflammatory cytokine production with tanshinones. US20090221542 (2009).
69. Fink, M.P., Ulloa, L., Tracey, K.J., Delude, R. Method of using pyruvate and/or its derivatives for the treatment of cytokinemediated inflammatory. US6943190 (2003).
70. Habgood, G.J., Elbaum, D. Anabaseine derivatives, pharmaceutical compositions and method of use thereof. US7662965 (2007).
71. Bianchi, M.E., Bonaldi, T., Scaffidi, P., Mueller, S., Degryse, B. HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases. US7754217 (2001).
72. Clark, R.B., Elbaum, D. Piperazines, pharmaceutical compositions and methods of use thereof. US7943622 (2007).
73. Tracey, K.J., Wang, H. Antagonists of HMG1 for treating inflammatory conditions. US8053206 (2009).
74. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99(19): 12351-6.
75. Fink MP. Ethyl pyruvate: A novel treatment for sepsis. Curr Drug Targets 2007; 8(4): 515-8.
76. Fink MP. Ethyl pyruvate: A novel anti-inflammatory agent. J Intern Med 2007; 261(4): 349-62.
77. Tracey, K.J., Yang, H., Warren Jr, H.S., Fink, M.P. Use of HMG fragments as anti-inflammatory agents. US7304034 (2002), US20030060410 (2003) & US20030144201 (2003).
78. O'Keefe, T.L. Use of HMGB fragments as anti-inflammatory agents. US20040141948 (2004).
79. Newman, W. HMGB1 combination therapies. US20040156851 (2004).
80. Newman, W. Combination therapies of HMGB and complement inhibitors against inflammation. US20080075728 (2008).
81. Traversa, S., Lorenzetto, C., Mainero, V., Morena, S., Fumero, S., Beccaria, L. Polymer conjugates of BOX-A of HMGB1 and BOXA variants of HMGB1. US20090324677 (2009).
82. Fumero, S., Pilato, Rossa, L.B.R., Barone, D.G., Drittanti, L., Guyon, T., Borelly, G., Canepa, B., Lorenzetto, C. Use of polypeptides obtained through systematic mutatuins of single amino acids of human and non-human box-A of HMGB1 to prevent and or antagonize pathologies induced by HMGB1. US20110052493 (2011).
83. Fumero, S., Pilato, Rossa, L.B.R., Barone, D.G., Drittanti, L., Guyon, T., Borelly, G., Canepa, B., Lorenzetto, C. Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). US7635679 (2007).
84. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101(7): 2652-60.
85. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123(3): 790-802.
86. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405(6784): 354-60.
87. Susa Y, Masuda Y, Imaizumi H, Namiki A. Neutralization of receptor for advanced glycation end-products and high mobility group box-1 attenuates septic diaphragm dysfunction in rats with peritonitis. Crit Care Med 2009; 37(9): 2619-24.
88. O'Keefe, T.L., Luciano, P., Qin, S. RAGE protein derivatives. US20060057679 (2006).
89. Anderson, G.M., Jordan, R., Picha, K. sRAGE mimetibody, compositions, methods and uses. US20060084145 (2006).
90. Jin, P., Shepard, H.M. Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same. US20070087406 (2007).
91. Clancy, B., Pittman, D., Tan, X.Y., Tchistiakova, L., Sreekumar, K.R., Paulsen, J.E., Widom, A., Piche-Nicholas, N., Sun, Y. Methods and compositions for antagonism of RAGE. US20070286858 (2007).
92. Kennedy, T.P. Method for blocking ligation of the Receptor for Advanced Glycation end-products (RAGE). US20090036405 (2009).
93. Wu, H.L., Shi, G.Y. Methods for binding Lewis Y antigen. US20100113568 (2010).
94. Hufton, S.E., Finlay, W.J.J., Cunningham, O.M., Sheehan, A.D., Germaine, X., Lambert, M.A. Humanized anti-RAGE antibody. US20100143349 (2010).
95. Logsdon, C.D., Arumugam, T. Antagonists of the receptor for advanced glycantion end-produtcts (RAGE). US20100249038 (2010).
96. Schmidt, A.M., Ferrante, A. Song, F. Uses of RAGE antagonists for treating obesity and related diseases. US20100254983 (2010).
97. Prestwich, G.D., Zhang, J., Kennedy, T.P., Rao, N.V., Xu, X. Alkylated semi-synthetic glycosaminoglycan ethers, and methods of making and using thereof. US20100317616 (2010).
98. Strakhova, M.I., Brederson, J.D. Antibodies to receptor for advanced glycantion end-produtcts (RAGE) and uses thereof. US20110104174 (2011).
99. Mjalli, A.M.M., Tian, Y.E., Webster, J.C., Rothlein, R. Rage fusion proteins. US7981423 (2005).
100. Mjalli, A.M.M., Rothlein, R., Tian, Y.E., Webster, J.C., Benjamin, E.J. RAGE fusion proteins, formulations, and methods of use thereof. US7981424 (2007).
101. Tracey, K.J., Yang, H. Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents. US7220723 (2003).
102. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26(2): 174-9.
103. Tracey, K.J., Yang, H. Combination therapy with inhibitors of HMGB and caspase for the treatment of inflammatory diseases. US20100040607 (2010).
104. Muzykantov, V.R., Zaitsev, S.V., Ding, B.S., Cines, D.B. Targeting recombinant therapeutics to circulating red blood cells. US20100285015 (2010).
105. Muzykantov, V.R., Ding, B.S., Cines, D.B., Gottstein, C., Albelda, S.M. Compositions containing thrombomodulin domains and uses thereof. US20110262466 (2011).
106. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264(9): 4743-6.
107. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115(5): 1267-74.
108. Bartunek J, Vanderheyden M. Inflammation and related biomarkers in cardiovascular disease. Biomark Med 2012; 6(1): 1-3.